Login to Your Account

NewCo News

NuCana BioMed Gets $10.5M For ProTide Cancer Drugs

By Cormac Sheridan
BioWorld Today Correspondent

Wednesday, November 30, 2011
NuCana BioMed Ltd. raised £6.74 million (US$10.5 million) in a Series A round to advance a series of modified nucleoside analogues in cancer indications and has set its sights on becoming the Inhibitex Inc. or even the Pharmasset Inc. of the cancer world.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription